Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)

NCT ID: NCT04838717

Last Updated: 2025-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-06
• Study Completion Date: 2025-07-23

Brief Summary

According to European and US Centers for Disease Control and Prevention (CDC) guidelines, the recommended treatment for uncomplicated early syphilis in adults (i.e. primary, secondary and early latent) is a single intramuscular injection of 2.4 million units of benzathine benzylpenicillin G (BPG). Recent reviews have also recommended BPG as the first-line treatment of early syphilis, reporting a success rate of more than 90% over a large panel of studies. This form of the drug provides weeks of treponemicidal levels of penicillin in the blood, but does not efficiently cross the blood-brain barrier.

However, despite the use of BPG for almost 70 years and its status as the gold standard treatment for early syphilis, the need to administer this antibiotic parenterally has led to the use of second-line oral antibiotics, including firstgeneration macrolides, and then second-generation macrolides, such as azithromycin. Several African studies have shown 1 g azithromycin bid treatment for one day to be effective against early syphilis, but most authors agree that azithromycin should not generally be used as resistance to this macrolide is highly prevalent in Western countries. Moreover, a recent study by our group showed that more than 80% of the treponemal strains isolated in France harbor the mutation conferring resistance to azithromycin. The use of this alternative would, therefore, be highly unlikely to be effective in France. Tetracycline antibiotics have also been proposed as an alternative in patients with a contraindication for BPG or other forms of penicillin. Doxycycline, at a dose of 100 mg orally twice daily for 14 days, has been endorsed as a preferred alternative treatment, but few data are available concerning its efficacy. This issue is crucial, for two main reasons: there has been a recrudescence of early syphilis in most western countries over the last 20 years, increasing the need for BPG, and two periods of BPG shortage were experienced in 2013 and 2017, leading to the use of alternative treatments due to the temporary unavailability of BPG or its limitation to cases in which no other treatment was possible. Data for the manufacturing and distribution of antibiotics are not publicly available, but reports of limited availability, shortages, and price increases for old antibiotics suggest that the current system is too fragile to provide what should be a given in modern medicine: access to effective treatment for common and potentially severe bacterial infections. The recurrence of BPG shortages over the last five years has created an urgent need to demonstrate that doxycycline is safe, or at least as safe as BPG, for treating early syphilis. The investigators hypothesize that the recommended doxycycline regimen is not inferior to BPG and plan to test this hypothesis in a randomized clinical trial.

Conditions

Syphilis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BPG Arm

BPG injections will be performed at the participating center

Group Type: ACTIVE_COMPARATOR

BPG

Intervention Type: DRUG

intramuscular injection of 2.4 million units

Doxycycline

Intervention Type: DRUG

Oral: at a dose of 100 mg bid for 14 days

Doxycycline Arm

Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.

Group Type: EXPERIMENTAL

BPG

Intervention Type: DRUG

intramuscular injection of 2.4 million units

Doxycycline

Intervention Type: DRUG

Oral: at a dose of 100 mg bid for 14 days

Interventions

BPG

intramuscular injection of 2.4 million units

Intervention Type: DRUG

Doxycycline

Oral: at a dose of 100 mg bid for 14 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients aged ≥ 18 years
• Patients who, after the nature of the study has been explained to them, and before any protocol-specific procedures are performed, give informed consent in writing, in accordance with local regulatory requirements
• Patients with or without HIV infection and with syphilis infection in the early stages according to CDC criteria (primary syphilis, secondary syphilis and early latent syphilis of less than one year's duration)
• Patients with a positive non-treponemal assay result
• Patients available for participation and follow-up during the 6 months of the study
• Patients covered by the French health insurance system

Exclusion Criteria

• Individuals with a history of known hypersensitivity to doxycycline or any other antibiotic of the tetracycline family, BPG (hypersensitivity to the active substance benzathine benzylpenicillin, to other penicillins, to soy phospholipids, peanuts or any of the excipients in the product ; history of severe immediate hypersensitivity reactions (eg anaphylaxis) to other beta-lactams (examples: cephalosporins, carbapenemes or monobactams), lidocaïne (hypersensitivity to lidocaine hydrochloride, amide-linked local anesthetics, or any of the excipients listed in SPC) and / or any of the excipients of the specialties used in the study
• Patients with a negative non-treponemal assay result
• Patients receiving an anticoagulant therapy
• Individuals with contraindications for either of the study drugs
• Individuals treated with retinoids by general route
• Individuals with early and late neurosyphilis
• Individuals requiring doxycycline treatment
• Individuals with late syphilis, whether or not latent (e.g. cutaneous)
• Individuals with thrombocytopenia or coagulation disorders contraindicating intramuscular injections
• Women who are pregnant or breast-feeding, or of childbearing age not using or planning to use acceptable birth control measures;
• Individuals under a measure of legal protection or unable to consent
• Individuals participating in any clinical trial with another investigational product in the 28 days preceding the first study visit or intending to participate in another clinical study at any time during the course of this study.
• Recent exposure

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

URC-CIC Paris Descartes Necker Cochin

OTHER

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nicolas DUPIN, PhD & MD

Role: PRINCIPAL_INVESTIGATOR

APHP Assistance Publique des Hôpitaux de Paris

Locations

CHRU Jean Minjoz

Besançon, , France

Hôpital Henri Mondor

Créteil, , France

Hôpital de la Croix Rousse

Lyon, , France

Hôpital Hotel Dieu

Paris, , France

Hôpital Saint Louis - GeGIDD

Paris, , France

Hôpital Saint Louis - SMIT

Paris, , France

CHU Toulouse - Hôpital de la Grave - GeGIDD

Toulouse, , France

Countries

France

Other Identifiers

2019-003278-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

APHP180588

Identifier Type: -

Identifier Source: org_study_id